Oct 7 Sanofi :

* Says magnetic resonance imaging (MRI) data from its PhaseIII TEMSO study demonstrate that Aubagio (teriflunomide)significantly slowed brain volume loss (or atrophy) vs placeboover two years in people with relapsing multiple sclerosisSource text for Eikon: Further company coverage: (Reporting by Paris Newsroom)